Stenoparib, an Inhibitor of Cellular Poly(ADP-Ribose) Polymerase, Blocks Replication of the SARS-CoV-2 and HCoV-NL63 Human Coronaviruses In Vitro-Reference-Cited by-同舟云学术

Stenoparib, an Inhibitor of Cellular Poly(ADP-Ribose) Polymerase, Blocks Replication of the SARS-CoV-2 and HCoV-NL63 Human Coronaviruses In Vitro

Published:2021-02-23 Issue:1 Volume:12 Page:
ISSN:2150-7511
Container-title:mBio
language:en
Short-container-title:mBio

Author:

Stone Nathan E.¹,Jaramillo Sierra A.¹,Jones Ashley N.¹,Vazquez Adam J.¹,Martz Madison¹,Versluis Lora M.¹²,Raniere Marlee O.¹²,Nunnally Haley E.¹,Zarn Katherine E.¹,Nottingham Roxanne¹,Ng Ken R.¹,Sahl Jason W.¹²,Wagner David M.¹²^ORCID,Knudsen Steen³,Settles Erik W.¹²,Keim Paul¹²^ORCID,French Christopher T.¹²

Affiliation:

1. Pathogen and Microbiome Institute, Northern Arizona University, Flagstaff, Arizona, USA

2. Department of Biological Sciences, Northern Arizona University, Flagstaff, Arizona, USA

3. Allarity Therapeutics, Hørsholm, Denmark

Abstract

New therapeutics are urgently needed in the fight against COVID-19. Repurposing drugs that are either already approved for human use or are in advanced stages of the approval process can facilitate more rapid advances toward this goal.

Funder

The Flinn Foundation

Cowden Endowment for Microbiology

Allarity Therapeutics

Publisher

American Society for Microbiology

Subject

Virology,Microbiology

Link

https://journals.asm.org/doi/pdf/10.1128/mBio.03495-20

Reference55 articles.

1. Characteristics of SARS-CoV-2 and COVID-19